Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS & spliceosome mutations скачать в хорошем качестве

Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS & spliceosome mutations

Samuel Urrutia, MD, Washington University in St. Louis, St. Louis, MO, comments on a study investigating the causes of death in patients with myelodysplastic syndromes (MDS) and spliceosome mutations. Dr Urrutia notes that the study elucidated that the IPSS-M classification, based on mutational profile, was better at stratifying patients by risk of transformation to acute myeloid leukemia (AML) than the IPSS-R classification, which is based on cytogenetics. While some patients classified as low-risk by IPSS-R experienced transformation to AML, zero transformations were observed in IPSS-M low-risk patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.